» Articles » PMID: 34062883

Ion-Complex Microcrystal Formulation Provides Sustained Delivery of a Multimodal Kinase Inhibitor from the Subconjunctival Space for Protection of Retinal Ganglion Cells

Abstract

Glaucoma is the leading cause of irreversible blindness worldwide. Elevated intraocular pressure (IOP) is one of the major risk factors for glaucoma onset and progression, and available pharmaceutical interventions are exclusively targeted at IOP lowering. However, degeneration of retinal ganglion cells (RGCs) may continue to progress despite extensive lowering of IOP. A complementary strategy to IOP reduction is the use of neuroprotective agents that interrupt the process of cell death by mechanisms independent of IOP. Here, we describe an ion complexation approach for formulating microcrystals containing ~50% loading of a protein kinase inhibitor, sunitinib, to enhance survival of RGCs with subconjunctival injection. A single subconjunctival injection of sunitinib-pamoate complex (SPC) microcrystals provided 20 weeks of sustained retina drug levels, leading to neuroprotection in a rat model of optic nerve injury. Furthermore, subconjunctival injection of SPC microcrystals also led to therapeutic effects in a rat model of corneal neovascularization. Importantly, therapeutically relevant retina drug concentrations were achieved with subconjunctival injection of SPC microcrystals in pigs. For a chronic disease such as glaucoma, a formulation that provides sustained therapeutic effects to complement IOP lowering therapies could provide improved disease management and promote patient quality of life.

Citing Articles

Preservation of Murine Whole Eyes With Supplemented UW Cold Storage Solution: Anatomical Considerations.

Muench N, Schmitt H, Schlamp C, Su A, Washington K, Nickells R Transl Vis Sci Technol. 2024; 13(11):24.

PMID: 39560629 PMC: 11578148. DOI: 10.1167/tvst.13.11.24.


A Glucose-Responsive Hydrogel Inhibits Primary and Secondary BRB Injury for Retinal Microenvironment Remodeling in Diabetic Retinopathy.

Zhou Y, Zhao C, Shi Z, Heger Z, Jing H, Shi Z Adv Sci (Weinh). 2024; 11(32):e2402368.

PMID: 39031576 PMC: 11348052. DOI: 10.1002/advs.202402368.


Next generation therapeutics for retinal neurodegenerative diseases.

Appell M, Pejavar J, Pasupathy A, Rompicharla S, Abbasi S, Malmberg K J Control Release. 2024; 367:708-736.

PMID: 38295996 PMC: 10960710. DOI: 10.1016/j.jconrel.2024.01.063.


Long-Acting Ocular Injectables: Are We Looking In The Right Direction?.

Dang M, Shoichet M Adv Sci (Weinh). 2023; 11(8):e2306463.

PMID: 38018313 PMC: 10885661. DOI: 10.1002/advs.202306463.


Engineered peptide-drug conjugate provides sustained protection of retinal ganglion cells with topical administration in rats.

Hsueh H, Chou R, Rai U, Kolodziejski P, Liyanage W, Pejavar J J Control Release. 2023; 362:371-380.

PMID: 37657693 PMC: 10591956. DOI: 10.1016/j.jconrel.2023.08.058.


References
1.
Becerra E, Morescalchi F, Gandolfo F, Danzi P, Nascimbeni G, Arcidiacono B . Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration. Curr Drug Targets. 2010; 12(2):149-72. DOI: 10.2174/138945011794182746. View

2.
Kim Y, Shin M, Hackett S, Hsueh H, Lima E Silva R, Date A . Gelling hypotonic polymer solution for extended topical drug delivery to the eye. Nat Biomed Eng. 2020; 4(11):1053-1062. PMC: 7655548. DOI: 10.1038/s41551-020-00606-8. View

3.
Welsbie D, Yang Z, Ge Y, Mitchell K, Zhou X, Martin S . Functional genomic screening identifies dual leucine zipper kinase as a key mediator of retinal ganglion cell death. Proc Natl Acad Sci U S A. 2013; 110(10):4045-50. PMC: 3593842. DOI: 10.1073/pnas.1211284110. View

4.
Prausnitz M, Noonan J . Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1999; 87(12):1479-88. DOI: 10.1021/js9802594. View

5.
Numakura K, Fujiyama N, Takahashi M, Igarashi R, Tsuruta H, Maeno A . Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients. Oncotarget. 2018; 9(38):25277-25284. PMC: 5982748. DOI: 10.18632/oncotarget.25423. View